• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    5/10/24 8:07:23 AM ET
    $AEMD
    $ALZN
    $BFRI
    $GH
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEMD alert in real time by email

    Gainers

    • Aethlon Medical (NASDAQ:AEMD) stock moved upwards by 129.0% to $2.7 during Friday's pre-market session. The company's market cap stands at $7.1 million.
    • Novavax (NASDAQ:NVAX) shares rose 119.23% to $9.8. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out today.
    • Sensus Healthcare (NASDAQ:SRTS) stock moved upwards by 51.18% to $5.76. The company's market cap stands at $94.4 million. As per the news, the Q1 earnings report came out yesterday.
    • Natera (NASDAQ:NTRA) shares moved upwards by 20.31% to $114.96. The market value of their outstanding shares is at $14.0 billion. The company's, Q1 earnings came out yesterday.
    • XTL Biopharmaceuticals (NASDAQ:XTLB) shares rose 16.25% to $2.79. The market value of their outstanding shares is at $15.2 million.
    • Guardant Health (NASDAQ:GH) shares moved upwards by 14.45% to $22.25. The market value of their outstanding shares is at $2.7 billion. The company's, Q1 earnings came out yesterday.

    Losers

    • Macrogenics (NASDAQ:MGNX) shares declined by 67.0% to $4.84 during Friday's pre-market session. The market value of their outstanding shares is at $302.7 million. As per the press release, Q1 earnings came out yesterday.
    • Progyny (NASDAQ:PGNY) stock fell 25.54% to $24.2. The market value of their outstanding shares is at $2.3 billion. As per the press release, Q1 earnings came out yesterday.
    • Protalix BioTherapeutics (AMEX:PLX) shares decreased by 16.0% to $1.05. The company's market cap stands at $76.9 million. As per the news, the Q1 earnings report came out today.
    • Biofrontera (NASDAQ:BFRI) stock fell 14.56% to $1.35. The company's market cap stands at $6.8 million.
    • Alzamend Neuro (NASDAQ:ALZN) stock decreased by 9.84% to $0.53. The company's market cap stands at $3.6 million.
    • Gritstone Bio (NASDAQ:GRTS) shares declined by 9.54% to $0.88. The company's market cap stands at $94.2 million. The company's, Q1 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AEMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEMD
    $ALZN
    $BFRI
    $GH

    CompanyDatePrice TargetRatingAnalyst
    Guardant Health Inc.
    $GH
    2/20/2026$125.00 → $135.00Buy
    Canaccord Genuity
    Guardant Health Inc.
    $GH
    2/17/2026$120.00Outperform
    Robert W. Baird
    Progyny Inc.
    $PGNY
    1/20/2026$30.00Mkt Perform → Mkt Outperform
    Citizens JMP
    Progyny Inc.
    $PGNY
    1/8/2026$34.00Hold → Buy
    Truist
    Natera Inc.
    $NTRA
    1/7/2026$300.00Buy
    Citigroup
    Guardant Health Inc.
    $GH
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Progyny Inc.
    $PGNY
    12/9/2025$29.00Overweight
    Barclays
    Natera Inc.
    $NTRA
    12/2/2025$265.00Overweight
    Morgan Stanley
    More analyst ratings

    $AEMD
    $ALZN
    $BFRI
    $GH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Bashan Dror bought $101,360 worth of shares (56,000 units at $1.81), increasing direct ownership by 42% to 188,516 units (SEC Form 4)

    4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

    12/23/25 7:25:58 AM ET
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sachetta Eric bought $27,510 worth of shares (7,000 units at $3.93), increasing direct ownership by 5% to 140,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/21/25 2:28:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    Director Sachetta Eric bought $11,250 worth of shares (2,500 units at $4.50), increasing direct ownership by 2% to 133,113 units (SEC Form 4)

    4 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    11/20/25 2:03:11 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mignone Roberto converted options into 264 shares, increasing direct ownership by 7% to 4,223 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    2/23/26 5:47:02 PM ET
    $GH
    Medical Specialities
    Health Care

    Director Hidalgo Medina Manuel converted options into 232 shares, increasing direct ownership by 18% to 1,493 units (SEC Form 4)

    4 - Guardant Health, Inc. (0001576280) (Issuer)

    2/18/26 4:27:49 PM ET
    $GH
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Biscotti Larry Joseph

    3 - Sensus Healthcare, Inc. (0001494891) (Issuer)

    2/18/26 3:48:31 PM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Presenting on Emerging Growth Conference 90 Day 1 on February 25; Register to live stream

    MIAMI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 90th Emerging Growth Conference on February 25 & 26, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 - WednesdayFebruary 25, 2026 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go

    2/24/26 7:00:00 AM ET
    $AEMD
    $ASPI
    $CLNN
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

    Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

    Interventional trial validates adaptive Signatera-guided treatment approach, achieving strong 63% response rate while reducing chemotherapy exposure in 74% of patients Results selected for oral plenary at 2026 Multidisciplinary Head and Neck Cancers Symposium (MHNCS) Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced results from the SINERGY trial, a Phase 2 study in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Data was recently presented in an oral plenary at the 2026 MHNCS. Approximately 73K patients are diagnosed with head and neck cancer in the U.S. annually.1 The current standard of care for R/M HNSCC

    2/24/26 6:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial

    ROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that the U. S. Food and Drug Administration (FDA) has placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, an investigational, bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with gynecologic cancers. Under the partial clinical hold, no new patients will be enrolled in the LINNET study until the partial hold is lifted by the FDA. Current study participants may continue to receive study drug. The FDA's partial clinical

    2/23/26 6:14:00 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    July 30, 2024 - FDA Roundup: July 30, 2024

    For Immediate Release: July 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA is announcing the fiscal year (FY) 2025 user fee rates for importers approved to participate in the Voluntary Qualified Importer Program (VQIP) and accreditation and certification bodies interested in participating in the Accredited Third-Party C

    7/30/24 3:38:18 PM ET
    $GH
    Medical Specialities
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity reiterated coverage on Guardant Health with a new price target

    Canaccord Genuity reiterated coverage of Guardant Health with a rating of Buy and set a new price target of $135.00 from $125.00 previously

    2/20/26 8:00:16 AM ET
    $GH
    Medical Specialities
    Health Care

    Robert W. Baird initiated coverage on Guardant Health with a new price target

    Robert W. Baird initiated coverage of Guardant Health with a rating of Outperform and set a new price target of $120.00

    2/17/26 8:18:22 AM ET
    $GH
    Medical Specialities
    Health Care

    Progyny upgraded by Citizens JMP with a new price target

    Citizens JMP upgraded Progyny from Mkt Perform to Mkt Outperform and set a new price target of $30.00

    1/20/26 8:45:21 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    SEC Filings

    View All

    Aethlon Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - AETHLON MEDICAL INC (0000882291) (Filer)

    2/23/26 4:15:32 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    SEC Form 6-K filed by XTL Biopharmaceuticals Ltd.

    6-K - XTL BIOPHARMACEUTICALS LTD (0001023549) (Filer)

    2/23/26 4:05:27 PM ET
    $XTLB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Guardant Health Inc.

    S-8 - Guardant Health, Inc. (0001576280) (Filer)

    2/20/26 9:05:55 AM ET
    $GH
    Medical Specialities
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    Leadership Updates

    Live Leadership Updates

    View All

    Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

    Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference.SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's CEO and CFO, Jim Frakes in

    2/23/26 8:01:00 AM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    Octave Bioscience Expands Leadership Team with Appointment of Kirk Stockwood Senior Vice President, Commercial

    Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson's disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave's commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years of leadership experience in specialty diagnostics and tools, with a proven track record of commercial scaling within public and private companies. Most recently as Vice President of Sales at Quanterix, he led a global team focused on

    1/8/26 4:01:00 PM ET
    $NTRA
    Medical Specialities
    Health Care

    Sensus Healthcare Appoints Larry Biscotti to its Board of Directors

    Sensus Healthcare, Inc. (NASDAQ:SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, today announced the appointment of Larry Biscotti to its Board of Directors, effective immediately. With this appointment the Sensus Healthcare Board has six Directors, including four independent Directors. Mr. Biscotti brings more than 25 years of executive leadership experience in the medical device and healthcare technology sectors, with an extensive background in driving commercial strategy, expanding global market share and launching advanced imaging and oncology technologi

    1/7/26 8:30:00 AM ET
    $SRTS
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    Financials

    Live finance-specific insights

    View All

    Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

    GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (NASDAQ:NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 a.m. Eastern Time (ET) on Thursday, February 26, 2026. Details of the event and replay are as follows:Conference call details:Date:February 26, 2026Time:8:30 a.m. ETURL to register phone:Register HereDial-in number:(888) 880-3330 (U.S.) or(+1) (646) 357-8766 (International)Webcast:ir.novavax.com/eventsParticipants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.Participants can als

    2/19/26 8:00:00 AM ET
    $NVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

    Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2025, after the market closes on Feb. 26, 2026. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET). Earnings Conference Call Information Event: Natera's Fourth Quarter & Full Year 2025 Financial Results Date: February 26, 2026 Time: 1:30 p.m. PT (4:30 p.m. ET) Live Dial-In:   1-888-770-7321 (Domestic) 1-929-201-7107 (International) Conference ID: 7684785 Webcast: https://events.q4inc.com/at

    2/17/26 9:00:00 AM ET
    $NTRA
    Medical Specialities
    Health Care

    Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

    Clinical and research programs continue to advance, supported by year-to-date cost efficiencies Conference Call Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2025, and provided an update on recent developments.  Key Highlights Maintained Nasdaq Listing: Continued compliance with Nasdaq listing requirements, with all prior compliance matters remaining resolved. Clinical Progress: Cohort 2 of the Australian oncology tr

    2/12/26 4:15:00 PM ET
    $AEMD
    Medical/Dental Instruments
    Health Care

    $AEMD
    $ALZN
    $BFRI
    $GH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Progyny Inc.

    SC 13G/A - Progyny, Inc. (0001551306) (Subject)

    12/6/24 10:11:35 AM ET
    $PGNY
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by MacroGenics Inc.

    SC 13G - MACROGENICS INC (0001125345) (Subject)

    11/20/24 10:44:27 AM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by MacroGenics Inc.

    SC 13G/A - MACROGENICS INC (0001125345) (Subject)

    11/14/24 5:13:06 PM ET
    $MGNX
    Biotechnology: Pharmaceutical Preparations
    Health Care